Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers

In a new study, compelling new evidence is presented regarding the association between alterations in the human epidermal growth factor receptor type 2 (HER2) amplicon and incremental sensitivity to anthracycline-based adjuvant therapy for breast cancers. This report is the latest in a series of pub...

Full description

Saved in:
Bibliographic Details
Published in:JNCI : Journal of the National Cancer Institute 2009-05, Vol.101 (9), p.615-618
Main Authors: Slamon, Dennis J., Press, Michael F.
Format: Article
Language:English
Subjects:
Anthracyclines - administration & dosage
Antigens, Neoplasm - genetics
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - enzymology
Breast Neoplasms - genetics
Chemotherapy
Chemotherapy, Adjuvant
Clinical Trials as Topic
DNA Topoisomerases, Type II - genetics
DNA-Binding Proteins - genetics
Female
Gene Amplification
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
Genes, erbB-2
Genetics
Humans
Medical research
Oligonucleotide Array Sequence Analysis
Poly-ADP-Ribose Binding Proteins
Predictive Value of Tests
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a new study, compelling new evidence is presented regarding the association between alterations in the human epidermal growth factor receptor type 2 (HER2) amplicon and incremental sensitivity to anthracycline-based adjuvant therapy for breast cancers. This report is the latest in a series of publications that question the generalized assumption that there is an incremental benefit to all breast cancer patients who receive anthracycline-based adjuvant therapy as opposed to non-anthracycline-containing adjuvant therapy. This premise has dominated the design of studies and clinical practice utilization for the vast majority of adjuvant regimens worldwide over the past 30 years. The widespread use of adjuvant anthracyclines is almost entirely based on the well-known meta-analysis published by the Early Breast Cancer Trialists' Collaborative Group, frequently referred to as the Oxford "Overview", rather than results from any single study.
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/djp092